Nabumetone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Nabumetone
- Nabumetone: From NSAID Anti-Inflammatory Therapy to Acromesomelic Dysplasia, Hunter-Thompson Type
Nabumetone: From NSAID Anti-Inflammatory Therapy to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Nabumetone is an NSAID prodrug whose active metabolite (6-MNA) inhibits COX enzymes. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare genetic skeletal disorder. No clinical trials and no publications currently support this prediction, and no plausible mechanistic link has been identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the US licence data provided (NSAID, COX inhibitor) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the listed licences are ANDA generics) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Nabumetone is an NSAID prodrug, and its active metabolite 6-MNA inhibits COX enzymes and prostaglandin synthesis.
For this predicted indication, the mechanistic link is weak. Acromesomelic dysplasia, Hunter-Thompson type, is a genetic skeletal dysplasia related to CDMP1/GDF5 growth-factor signaling. COX inhibition does not address that defect. The high TxGNN score (0.9999) is a graph-based prediction with no clinical or literature support in the provided data, so it should not be read as evidence of efficacy.
Among the top 10 predictions, only spondyloarthropathy, susceptibility to (rank 8, score 99.94%) has a biologically plausible rationale. NSAIDs are class-level first-line therapy for spondyloarthritis. This rationale comes from general pharmacology, not from supplied evidence, so it also remains L5. It is flagged as a research question.
Other predictions with only a symptomatic or speculative link:
- Pseudoachondroplasia: an NSAID may relieve joint pain but would not modify the underlying pathology.
- Rheumatoid nodulosis: an NSAID may relieve joint symptoms but is not known to resolve nodules.
- Myosclerosis: the link is speculative.
The remaining predictions (brachyolmia, brachyolmia-amelogenesis imperfecta syndrome, colobomatous microphthalmia-rhizomelic dysplasia syndrome, brachydactyly-syndactyly syndrome, WHIM syndrome) have no plausible link.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA078420 | Nabumetone | Tablet | Proficient Rx LP |
| ANDA078671 | Nabumetone | Tablet, film coated | Northwind Health Company, LLC |
| ANDA078420 | Nabumetone | Tablet | Westminster Pharmaceuticals, LLC |
| ANDA078671 | Nabumetone | Tablet, film coated | PD-Rx Pharmaceuticals, Inc. |
| ANDA091083 | Nabumetone | Tablet, film coated | Proficient Rx LP |
All listed forms are oral. In total, 20 licences are recorded and 5 are shown here.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on the TxGNN score, with no trials, no literature and no plausible mechanistic link to a GDF5-related skeletal dysplasia. The evidence level is L5 and the decision stage is S0.
To proceed, the following is needed:
- FDA package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- A targeted literature search for nabumetone in axial spondyloarthritis, the most plausible candidate in this set
- Any preclinical or clinical evidence for the rank-1 indication before it is reconsidered
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.